GSK, Chinese Firm In Flu Vaccine Venture | June 15, 2009 Issue - Vol. 87 Issue 24 | Chemical & Engineering News
Volume 87 Issue 24 | p. 16 | Concentrates
Issue Date: June 15, 2009

GSK, Chinese Firm In Flu Vaccine Venture

Department: Business
Keywords: GSK, China, vaccines

GlaxoSmithKline and Shenzhen Neptunus Interlong Bio-Technique have formed a joint venture to make flu vaccines for the Chinese market. GSK will pay $34 million in cash and assets for a 40% stake in the venture, with Neptunus putting up $50 million for the rest. GSK has the right to buy a majority interest in the joint venture within the next two years. Neptunus has knowledge of the local flu market, and GSK contributes its adjuvant technology and vaccine development experience.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment